Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome

European Journal of Paediatric Neurology

Volumn 6, Issue 4, 2002, Pages 213-219

  Salman, Michael S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cognitive enhances; Down syndrome; Systematic review

Indexed keywords

5 HYDROXYTRYPTOPHAN; HYPOPHYSIS EXTRACT; MINERAL; NIALAMIDE; PIRACETAM; PYRIDOXINE; THIAMINE; VASOPRESSIN; VITAMIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN SYNDROME; DRUG EFFECT; HUMAN; INFANT; META ANALYSIS; NEWBORN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION;

EID: 0036378556     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejpn.2002.0596     Document Type: Article

References (36)

1. Steele J. Epidemiology: incidence, prevalence and size of the Down's syndrome population. In: Stratford B, Gunn P eds New Approaches to Down Syndrome. London: Cassell, 1996.
2. Marder E, Dennis J. Medical management of children with Down syndrome. Curr Paediatr 1997; 7: 1-7.
3. Anneren G, Pueschel SM. Preventative medical care. In: Stratford B, Gunn P eds New Approaches to Down Syndrome. London: Cassell, 1996.
4. Wishart JG. Avoidant learning styles and cognitive development in young children. In: Stratford B, Gunn P eds New Approaches to Down Syndrome. London: Cassell, 1996.
5. Goodman JF. Early intervention with delayed children: policies and pedagogy. In: Stratford B, Gunn P eds New Approaches to Down Syndrome. London: Cassell, 1996.
6. Hayes A. Family life in community context. In: Stratford B, Gunn P eds New Approaches to Down Syndrome. London: Cassell, 1996.
7. Pueschel SM. Down syndrome: defining problems and exposing 'useless therapy'. Consultant 1985; 25: 77-9; 82-84.
8. La Perchia P. Behavioural disorders, learning disabilities and megavitamin therapy. Adolescence 1987; 22: 729-738.
9. Ani C, Grantham-McGregor S, Muller D. Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol 2000; 42: 207-213.
10. Vernon MW, Sorkin EM. Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs and Aging 1991; 1: 17-35.
11. Siegal J. WHO calls for tighter controls on Internet. BMJ 1997; 314: 1504.
12. Prendiville W, Elbourne D, Chalmers I. The effects or routine Oxytocin administration in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1988; 95: 3-16.
13. Cohen JA. A coefficient of agreement for nominal scales. Educational Psychlogical Measurement 1960; 20: 37-46.
14. Arnold GL, Schulz EG, Rickett V, Krogh J, Kearns GL. Effect of Amantidine supplementation on Dopamine and developmental outcome in Down syndrome. Am J Hum Genet 1995; 57: 444.
15. Blackston RD, Loveland K, Richardson C et al. Controlled studies comparing early intervention programs versus supplemental nutritional therapies in children with Down syndrome. Am J Hum Gen 1997; 61(Suppl): A34.
16. Manning CA, Honn VJ, Stone WS et al. Glucose effects on cognition in adults with Down's syndrome. Neuropsych 1998; 12: 479-484.
17. Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down's syndrome. Lancet 2000; 356: 1409-1410.
18. Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-Hydroxytryptophan and Pyridoxine. Their effect in young children with Down syndrome. Am J Dis Child 1980; 134: 838-844.
19. Smith GF, Spiken D, Peterson CP et al. Use of megadoses of vitamins with minerals in Down syndrome. J Paediatr 1984; 105: 228-234.
20. Bidder R, Gray P, Newcombe R et al. The effects of multivitamin and minerals on children with Down syndrome. Dev Med Child Neurol 1989; 31: 532-537.
21. Bennett F, McClelland S, Kriegsmann E et al. Vitamin and mineral supplementation in Down syndrome. Paediatr 1983; 72: 707-713.
22. Eisenberg J, Hamburger-Bar R, Belmaker RH. The effect of Vasopressin treatment on learning in Down syndrome. J Neural Trans 1984; 60: 143-147.
23. Coleman M, Sabel S, Bhagavan HN et al. A double blind study of vitamin B6 in Down syndrome infants Part 1 - Clinical and biochemical results. J Ment Defic Res 1985; 29: 233-240.
24. Weathers C. Effects of nutritional supplementation on IQ and certain other variables associated with Down syndrome. Am J Ment Defic 1983; 88: 214-217.
25. Lonsdale D, Kissling CD. Clinical trials with Thiamine, Tetrahydrofurfuryl Disulfide (TTFD) in Down syndrome. J Orthomolec Med 1986; 1: 169-175.
26. Berg JM, Kirman BH, Stern J. Treatment of mongolism with pituitary extract. J Ment Sci 1961; 107: 475-480.
27. Heaton-Ward WA. Inference and suggestion in a clinical trial (Niamid in Mongolism). Br J Psych 1962; 108: 865-870.
28. Lobaugh NJ, Karaskov V, Rombough V et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. Arch Pediatr Adolesc Med 2001; 155: 442-448.
29. Whitehead RG. Vitamins, minerals, school children and IQ. BMJ 1991; 302: 548.
30. Schoenthaler S. Diet and IQ. Nature 1991; 352: 292.
31. Editorial. Brains and vitamins. Lancet 1991; 337: 587-588.
32. Schoenthaler S. Brains and vitamins. Lancet 1991; 337: 728-779.
33. Nelson M. Food, vitamins and IQ. Proc Nutr Soc 1991; 50: 29-35.
34. Share JB. Review of drug treatment for Down's syndrome persons. Am J Ment Defic 1976; 80: 388-393.
35. Airaksinen E. Effects of (oral) L-Tryptophan in Down syndrome. In: D Primrose ed Proceedings of the Third Congress, Vol 1: International Association for the Scientific Study of Mental Deficiency, 1973.
36. Coleman M. Results of a three year double blind study of the administration of 5-HTP to patients with Down syndrome. In: D Primrose ed Proceedings of the Third Congress, Vol 1: International Association for the Scientific Study of Mental Deficiency, 1973.